• MJHLS Brand Logo

© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.

AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access

April 24, 2024

Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.

AON Saves Over $243 Million With High Biosimilar Adoption

April 22, 2024

Sustainable Biosimilar Markets Achieve Widespread Market Uptake Through Collective Action

April 22, 2024

Navigating the Patent Thicket: Balancing Innovation, Biosimilar Access in the Biologics Market

April 21, 2024

Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch

April 20, 2024

Featured Content

Selecting Between Adalimumab Biosimilars for Your Patients

April 19th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.

Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

April 19th 2024

By Jamie T. Brogan, MSN, APRN, FNP-BC

Video

A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.

The Top 5 Biosimilar Articles for the Week of April 15

April 19th 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 15, 2024.

Julie Reed: Why 2024 Is Important for Biosimilars

April 17th 2024

By Skylar Jeremias

Article

Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.

Fresenius Kabi's Tocilizumab Biosimilar, Tyenne, Launches in US Market

April 16th 2024

By Rose McNulty

Article

Tyenne (tocilizumab-aazg) was the second tocilizumab biosimilar to be FDA approved, but it is the first to launch in the US.

Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval

April 16th 2024

By Skylar Jeremias

Article

Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.

The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability

April 16th 2024

By Skylar Jeremias

Article

Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.

BioRationality: Removing the Misconceptions Surrounding Interchangeability

April 15th 2024

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.

Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC

April 14th 2024

By Cameron Santoro

Article

Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.

What Clinicians Need to Know About Using Biosimilars to Treat IBD

April 13th 2024

By Deana Ferreri, PhD

Article

A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.